Lutetium-177 (Lu-177) is currently the most important therapeutic radionuclide and it will continue to be a key role player in the nuclear medicine field, as its half-life of 6.65 days allows logistic of production and supply of radioisotope and finished product. Currently there are over 70 radiopharmaceuticals for therapy in clinical trials and about 40% of them are based on Lu-177. This Coordinated Research Project (CRP) will identify potential carrier molecules that target some of the major cancers for labelling with Lu-177 using bifunctional agents and carry out preclinical evaluation towards the development of radiopharmaceuticals for targeted therapy. This CRP involves 16 Participating Countries from Europe, North and South America and Asia. Researchers from the Radiopharmaceutical Sciences Group of C2TN are members of this CRP and participated in the first meeting held in December 2023 at the headquarters of the IAEA in Vienna, Austria.
Coordinator at IST: Filipa Mendes – fmendes@ctn.tecnico.ulisboa.pt
Website of the project: https://www.iaea.org/projects/crp/f22078